Last Updated on October 11, 2024 by The Health Master
Aurobindo Pharma
Pharmaceutical leader Aurobindo Pharma achieves a significant milestone with the USFDA’s Voluntary Action Indicated classification for Unit III in Bachupally Village, Telangana.
Aurobindo Pharma, a prominent player in the pharmaceutical industry, recently received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Unit III located in Bachupally Village, Telangana.
This marks a significant achievement for the company, solidifying its commitment to quality and compliance.
USFDA Inspection Details
The USFDA conducted a comprehensive inspection of Aurobindo Pharma Limited’s Unit III in Bachupally Village, Telangana, spanning from July 14 to July 21.
The inspection aimed to assess the facility’s adherence to stringent regulatory standards.
Observations and Form 483
On July 21, the USFDA issued Form 483, which contained three observations for the mentioned unit.
It’s important to note that a Form 483 is a document issued to a firm’s management at the conclusion of an inspection, listing any conditions that may constitute violations of the Food, Drug, and Cosmetic Act.
Voluntary Action Indicated (VAI) Status
Despite the observations, the USFDA classified Unit III as Voluntary Action Indicated (VAI).
This designation signifies that while noteworthy deficiencies were identified during the inspection, they do not necessitate immediate regulatory action.
This status is a positive outcome, allowing the company to continue its operations without interruption.
Implications of VAI Status
The VAI classification empowers Aurobindo Pharma to pursue approvals for new drugs from this particular facility.
Additionally, it grants the company the ability to continue the production and commercialization of previously approved medications.
This designation holds substantial significance, as it represents the second-highest classification attainable by a pharmaceutical manufacturing facility under the scrutiny of the USFDA.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issued EIR to Torrent Pharma: Gujarat
Procedural lapses flagged at Aurobindo Pharma by USFDA: Telangana
USFDA completes PADE inspection at Marksans with 2 observations
USFDA concludes inspection at Granules Pharma with zero observations
USFDA concludes inspection at Gland Pharma with zero observation
Understanding GMP, cGMP, and WHO-GMP
Quality Assurance in the Pharmaceutical Industry
Duties and responsibilities of QA person in Pharma Industry
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Drug alert: 7 drugs identified as NSQ in Rajasthan
Telangana IPGA Hosts Workshop on Good Teaching Practices
USFDA Approval granted for Isotretinoin Capsules for Acne Treatment
Govt to implement uniform measures for Drug Quality and Safety
DCGI issues advisory on this fake Cancer Injection
Revolutionary Weight Loss Drug, KDS2010, shows promise in Clinical Trials
Delhi High Court prioritizes hearing on ban on Cough Syrup
Drug alert: WHO issues urgent Alert over fake liver drug in India and Turkey
Delhi High Court upholds inclusion of Medical Devices as Drugs under…
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
